Therapeutic effect of budesonide suspension combined with montelukast sodium in the treatment of children with chest tightness variant asthma

Objective To observe the clinical efficacy and safety of budesonide suspension atomized inhalation combined with oral montelukast sodium in children with chest tightness variant asthma(CTVA). Methods Thirty children with CTVA clinically diagnosed in the First Affiliated Hospital of Bengbu Medical College from September 2018 and September 2019 were enrolled. All children completed pulmonary function tests and chest tightness scores(r-ACQ) at the initial diagnosis, and all had positive bronchial challenge test or positive bronchodilator test. The children were routinely treated with inhaled budesonide suspension and/or oral montelukast sodium and revisited 2-4 weeks after treatment. The main indicators of pulmonary function before and after treatment of children [1 second forced expiratory volume(FEV₁), rate of 1 second(FEV₁/FVC%), maximum expiratory flow rate(PEF), forced exhalation 25%, 50%, 75% vital capacity peak expiratory flow rate(FEF₂₅, FEF₅₀, FEF₇₅), maximum expiratory flow rate(MMEF)] were analyzed. The clinical symptoms, r-ACQ scores and the occurrence of adverse reactions were followed up. Results The remission rate of chest tightness after treatment was 93.3%, and the r-ACQ score of chest tightness after treatment was lower than that before treatment, which was consistent with the remission of clinical symptoms. After 2-4 weeks of treatment, the lung function indexes of the children were compared with before treatment: FEV₁(F=3.623, P=0.031), FEV₁/FVC%(F=3.188, P=0.046), PEF(F=4.506, P=0.014), FEF₂₅(F=8.518, P<0.001), FEF₅₀(F=9.794, P<0.001), FEF₇₅(F=8.736, P<0.001), and MMEF(F=8.923, P<0.001). No obvious adverse reactions occurred during the treatment. Conclusion Budesonide suspension combined with montelukast sodium can effectively alleviate the clinical symptoms of children with CTVA, and no obvious adverse reactions.